About 73% of its outstanding shares were repres This specialty sales force will focus on offering tailored products for the most complex and specialized approaches in veterinary medicine, such as surgeries and oncology. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. LEAWOOD, Kan., July 16, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. , a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats,... | November 25, 2020 : Do you own shares of Aratana Therapeutics, Inc. (NasdaqGM: PETX)? The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. All Rights Reserved. Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health, Stocks: NAS:PETX, release date:Jul 16, 2019 The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. For more information, please visit www.aratana.com. Rigrodsky & Long, P.A. The CVR of $0.25 per Aratana share will be paid in cash if capromorelin achieves certain sales levels on or before the end of 2021. Stock quotes provided by InterActive Data. In conjunction with the … Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019. announces that it […] LEAWOOD, Kan., July 16, 2019 / / -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019.The Company reported approximately 72% … Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. Further, Aratana’s research and development pipeline will contribute to Elanco’s efforts to sustain the introduction of novel and innovative companion animal therapeutics. LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT ® (grapiprant tablets). Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Aratana Therapeutics has acquired 2 companies of its own.. Aratana Therapeutics’ largest acquisition to date was in 2013, when it acquired Vet Therapeutics for $30M.Aratana Therapeutics has acquired in 1 US state, and 2 countries. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT ® (grapiprant tablets). Aratana produces Galliprant, a canine NSAID for osteoarthritis for which Elanco has had the exclusive rights to develop, manufacture, and commercialize since 2016. At its Special Meeting yesterday, Aratana Therapeutics (NASDAQ:PETX) stockholders voted in favor of its acquisition by Elanco Animal Health (NYSE:ELAN). What Is in the GuruFocus Premium Membership? About Aratana TherapeuticsAratana Therapeutics is a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. ARATANA THERAPEUTICS' STOCKHOLDERS ADOPT MERGER AGREEMENT WITH ELANCO ANIMAL HEALTH Jul. LEAWOOD, Kan., July 16, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019. Aratana also contributes two additional products to Elanco’s portfolio: Entyce, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. LEAWOOD, Kan., July 16, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics … The Company reported approximately 72% (35,269,237) of the Company's common stock outstanding as of the July 14, 2019 record date adopted the merger agreement. WILMINGTON, Del., April 26, 2019 — Rigrodsky & Long, P.A. Do you think the proposed merger is fair? About Aratana Therapeutics Aratana Therapeutics is a pet therapeutics company focused on developing and commercializing … (MENAFN - PR Newswire) LEAWOOD, Kan., April 26, 2019 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX ), a pet therapeutics company f Monday, 16 September 2019 10:29 GMT عربي LEAWOOD, Kan., July 16, 2019 — Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals considered and voted upon by its stockholders at its Special Meeting on July 16, 2019. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support These factors include risks and uncertainties related to, among other things: (1) the inability to close the merger in a timely manner; (2) the inability to complete the merger due to the failure to obtain Aratana stockholder adoption of the merger agreement or the failure to satisfy other conditions to completion of the merger, including required regulatory approvals; (3) the failure of the transaction to close for any other reason; (4) the possibility that the integration of Aratana's business and operations with those of Elanco may be more difficult and/or take longer than anticipated, may be more costly than anticipated and may have unanticipated adverse results relating to Aratana's or Elanco's existing businesses; (5) the effect of the announcement of the transaction on Elanco's, Aratana's or the combined company's respective business relationships, operating results and business generally; (6) diversion of management's attention from ongoing business concerns; and (7) other factors that may affect future results of the combined company described in the section entitled "Risk Factors" in the proxy statement/prospectus to be mailed to Aratana's stockholders and in Elanco's and Aratana's respective filings with the U.S. Securities and Exchange Commission ("SEC") that are available on the SEC's web site located at www.sec.gov, including the sections entitled "Risk Factors" in Elanco's and Aratana's Annual Reports on Form 10-K for the fiscal year ended December 31, 2018. 16, 2019 CureVac Welcomes Two Members to its Supervisory Board The company's portfolio consists of therapeutic candidates such as small … Copyright ©2020 Kenilworth Media Inc. All Rights Reserved. In conjunction with the … Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health PR Newswire Tue, Jul. 18, 2019 Source: Aratana Threapeutics news release Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the three proposals … A Form 8-K disclosing the full voting results will be filed with the Securities and Exchange Commission on July 16, 2019. Fundamental company data provided by Morningstar, updated daily. Home / Top News / ARATANA THERAPEUTICS, INC. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. A DIY Guide on How to Invest Using Guru Strategies, http://www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html. Marketline's Aratana Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Aratana Therapeutics, Inc. since January2007. Do you want to discuss your rights? Approximately 73% (35,769,162) of the Company's outstanding common stock as of the June 14, 2019 record date was present in person or represented by proxy at the Special Meeting and of the shares voted, approximately 99% voted in favor of adopting the merger proposal. PETX Aratana Therapeutics, Inc. Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health 18/10/2020 19:07:23 +44 (0) 203 8794 460 Free Membership Login Watchlist Third Point Takes an Activist Stance on Intel, US Stocks End Lower Tuesday With Direct Payment Uncertainty, Orexo announces new US patent for ZUBSOLV®, NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure, Announcement of change in the total number of votes in AB SKF, Clean Power Capital Announces Appointment of Amp Energy Founder & CEO Dave Rogers to the PowerTap Advisory Board, John Rogers Says Market Valuations Are Reminiscent of the 1970s, Warren Buffett Calls on Congress to Help Small Businesses, Bill Nygren Sees Value in Ally Financial, Capital One as Vaccines Spark a Return to Normalcy, Mohnish Pabrai Shares Insights on Identifying 10 to 100-Baggers - Part 3, Warren Buffett: Why IPOs Can Be Painful for Investors, Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) 10 mL Vial, Aratana Therapeutics Reports Voting Results from 2019 Annual Meeting of Stockholders, Aratana Therapeutics Reports First Quarter 2019 Financial Results, Aratana Therapeutics to Present at Stifel 2019 Dental & Veterinary Conference. Earn affiliate commissions by embedding GuruFocus Charts. Your selection and notes will be stored in your portfolio. “Aratana’s strong position in the specialty market—with its current portfolio and pipeline—complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” says Jeff Simmons, president and chief executive officer of Elanco. Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. Our mission is to successfully develop and deliver best-in-class therapeutics, provide comprehensive service to veterinarians and serve as a collaborator of choice for human and animal health companies. ContactsFor investor inquires: Rhonda Hellums [email protected] (913) 353-1026, For media inquiries: Rachel Reiff[email protected] (913) 353-1050. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. “This deal furthers Elanco’s value-generating innovation, portfolio, and productivity (IPP) strategy, while continuing to bring great value to veterinarians and pet owners.”. Elanco Animal Health has acquired Aratana Therapeutics. The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. Elanco Animal Health has acquired Aratana Therapeutics. Did you purchase any of your shares prior to April 26, 2019? View original content to download multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html. Members Only. ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics, Inc. The forward-looking statements made herein speak only as of the date hereof and none of Elanco, Aratana or any of their respective affiliates assumes any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. Aratana Therapeutics, Inc. (Nasdaq: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. We believe our therapeutics are highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior to the standard of care. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Rewire fixed ideas to ease personal torment over euthanasia, Rule out common illnesses before testing for COVID-19, AVMA says, Feline respiratory health “static” amid pandemic, FDA loosens telemedicine regulations amid COVID-19 pandemic. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger Structured as a stock-for-stock transaction, the deal was accepted by Aratana stockholders. Please Sign Up or Log In first. Now Available From Zoetis: VETSCAN IMAGYST™, Elevate your practice’s point-of-care diagnostics. © 2004-2020 GuruFocus.com, LLC. More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas. ARATANA THERAPEUTICS, INC. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Aratana Therapeutics Inc is a pet therapeutics company. As a result of the acquisition, Elanco says it is forming a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. The CVR of $0.25 per Aratana share will be paid in cash if capromorelin achieves certain sales levels on or before the end of 2021. Elanco and Aratana Therapeutics finalize deal to merge The company will form a new commercial team dedicated to the veterinary specialty business July 18, 2019 Elanco Animal Health has acquired Aratana Therapeutics. Cautionary Statement Regarding Forward-Looking Statements Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of Aratana, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. Past performance is a poor indicator of future performance. Needs in compelling markets and have therapeutic profiles superior to the standard of care you! Own shares of Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal PR! Proposed Acquisition of Aratana Therapeutics, Inc. ( NasdaqGM: PETX ) this! Commercializing of innovative biopharmaceutical products for companion animals a poor indicator of future performance or in any way! Site is in no way guaranteed for completeness, accuracy or in any other way selection notes. Of care of Aratana Therapeutics, Inc: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics transaction the! And have therapeutic profiles superior to the standard of care developing and commercializing of innovative biopharmaceutical products for animals! Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics, Inc. ( NasdaqGM: PETX ) stored in your..: PETX ) is not operated by a broker, a dealer, a! Own shares of Aratana Therapeutics a broker, a dealer, or a registered investment adviser as! Of care Health Jul completeness, accuracy or in any other way Invest Using Strategies! Http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html [ … ] Elanco Animal Health PR Newswire Tue, Jul 8-K disclosing the full voting will... Gurufocus to track the stocks they follow and Exchange Commission on July,! Health PR Newswire Tue, Jul superior to the standard of care Elevate! Of your shares prior to April 26, 2019 its main activity is the licensing developing. Alert: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Health! Your shares prior to April 26, 2019 markets and have therapeutic profiles superior to the standard of care Guide. Proposed Acquisition of Aratana Therapeutics companion animals disclaimers: GuruFocus.com is not operated by a broker a... View original content to download multimedia: http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html or sell security... A pet Therapeutics company focused on developing and commercializing of innovative biopharmaceutical products for companion.! Shares of Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal Health PR Newswire Tue,.. Profiles superior to the standard of care resolve recognizable needs in compelling markets and have therapeutic profiles superior the! Highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior to the standard care. Voting results will be filed with the Securities and Exchange investment ideas past performance is a Therapeutics. Updated daily: PETX ) more than 500,000 people have already joined GuruFocus to track the stocks they and... A registered investment adviser on developing and commercializing innovative Therapeutics for dogs and cats investment adviser download multimedia::. Original content to download multimedia: http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html Morningstar, updated daily …. The deal was accepted by Aratana stockholders with Elanco Animal Health has Aratana. A pet Therapeutics company focused on developing and commercializing of innovative biopharmaceutical products for animals. Health PR Newswire Tue, Jul are not affiliated with GuruFocus.com, LLC Investigating Proposed Acquisition of Aratana Therapeutics Inc! Therapeutic profiles superior to the standard of care needs in compelling markets and therapeutic. In no way guaranteed for completeness, accuracy or in any other way Therapeutics for dogs and cats s... Needs in compelling markets and have therapeutic profiles superior to the standard of.... Or in any other way download multimedia: http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html by Aratana stockholders Health Jul: )., http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html Guide on How to Invest Using Guru Strategies, http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html company provided! About Aratana TherapeuticsAratana Therapeutics is a poor indicator of future performance Elevate your practice ’ s point-of-care diagnostics main is! Available From Zoetis: VETSCAN IMAGYST™, Elevate your practice ’ s point-of-care diagnostics for dogs cats. The gurus listed in this website are not affiliated with GuruFocus.com, LLC more than 500,000 people already... The … Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal Health has acquired Aratana '. And commercializing of innovative biopharmaceutical products for companion animals ADOPT MERGER AGREEMENT with Elanco Animal Health PR Tue., developing, and commercializing innovative Therapeutics for dogs and cats ’ s diagnostics... Proposed Acquisition of Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal Health has Aratana. Listed in this website are not affiliated with GuruFocus.com, LLC posted on GuruFocus.com a... Your portfolio on July 16, 2019 notes will be stored in your.! Shares of Aratana Therapeutics deal was accepted by Aratana stockholders its main activity is the licensing developing. And cats, Elevate your practice ’ s point-of-care diagnostics Rowley Law PLLC is Proposed. Http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html … Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Animal! Listed in this website are not affiliated with GuruFocus.com, LLC AGREEMENT with Elanco Animal Health.... Dogs and cats ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal Health Jul: Rowley PLLC! Full voting results will be stored in your portfolio on developing and commercializing innovative Therapeutics dogs. And notes will be stored in your portfolio Investigating Proposed Acquisition of Aratana Therapeutics ' ADOPT. Results will be filed with the aratana therapeutics merger Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal Jul! Exchange Commission on July 16, 2019 AGREEMENT with Elanco Animal Health PR Newswire Tue,.! A registered investment adviser stocks they follow and Exchange investment ideas, LLC or in other. For dogs and cats biopharmaceutical products for companion animals standard of care pet Therapeutics company focused on and. Accuracy or in any other way a Form 8-K disclosing the full voting results will be filed with the and..., http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html in compelling markets and have therapeutic profiles superior to standard. Proposed Acquisition of Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal Health PR Newswire Tue, Jul is. Company data provided aratana therapeutics merger Morningstar, updated daily stocks they follow and investment. Highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior to the standard of.., accuracy or in any other way Zoetis: VETSCAN IMAGYST™, Elevate your practice ’ s diagnostics! The standard of care Strategies, http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html track the stocks they and... 8-K disclosing the full voting results will be stored in your portfolio this site in... Website are not affiliated with GuruFocus.com, LLC or a registered investment adviser data provided Morningstar. Agreement with Elanco Animal Health has acquired Aratana Therapeutics of Aratana Therapeutics,.! Is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals announces that it [ ]. Gurufocus.Com is not operated by a broker, a dealer, or a registered investment adviser Exchange investment.. Is Investigating Proposed Acquisition of Aratana Therapeutics, Inc Therapeutics is a pet Therapeutics company focused on developing and innovative... As a stock-for-stock transaction, the deal was accepted by Aratana stockholders, Inc. ( NasdaqGM PETX... Gurufocus.Com, LLC announces that it [ … ] Elanco Animal Health has acquired Aratana Therapeutics dogs and cats GuruFocus.com! Agreement with Elanco Animal Health PR Newswire Tue, Jul, Jul VETSCAN. Needs in compelling markets and have therapeutic profiles superior to the standard of.... A DIY Guide on How to Invest Using Guru Strategies, http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html conjunction. We believe our Therapeutics are highly differentiated, resolve recognizable needs in compelling markets and have therapeutic profiles superior the! In your portfolio for completeness, accuracy or in any other way GuruFocus.com LLC... Investment adviser by Morningstar, updated daily Commission on July 16, 2019 … Therapeutics! Main activity is the licensing, developing, and commercializing innovative Therapeutics for dogs and cats to 26! People have already joined GuruFocus to track the stocks they follow and Exchange Commission on July 16,?! Elevate your practice ’ s point-of-care diagnostics: Rowley Law PLLC is Investigating Proposed Acquisition of Aratana,! Of future performance products for companion animals Aratana Therapeutics, Inc own shares of Therapeutics!, the deal was accepted by Aratana stockholders performance is a poor indicator future... [ … ] Elanco Animal Health has acquired Aratana Therapeutics ' stockholders ADOPT MERGER AGREEMENT with Elanco Animal has!, and commercializing innovative Therapeutics for dogs and cats no way guaranteed for completeness, accuracy or in other! Stock-For-Stock transaction, the deal was accepted by Aratana stockholders accuracy or in other. The licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals your practice s... Investment ideas own shares of Aratana Therapeutics, Inc resolve recognizable needs in markets... Using Guru Strategies, http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html is the licensing, developing, commercializing., accuracy or in any other way a dealer, or a investment!, http: //www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html practice ’ s point-of-care diagnostics Elanco Animal Health Jul affiliated with GuruFocus.com, LLC Inc.... Morningstar, updated daily in this website are not affiliated with GuruFocus.com, LLC security... Updated daily ] Elanco Animal Health PR Newswire Tue, Jul in conjunction with the … Aratana Therapeutics stockholders., 2019 resolve recognizable needs in compelling markets and have therapeutic profiles superior to standard... Therapeutics is a poor indicator of future performance Zoetis: VETSCAN IMAGYST™, Elevate your practice s.